The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.
The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.
Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.
The Department of Nuclear Medicine has 4 units:
1) Conventional nuclear medicine
This unit offers all the usual non-PET examinations, using either gamma-emitting radionuclides, or substances labelled using gamma-emitting radioelements. In 2016, the Department of Nuclear Medicine carried out 3500 “conventional” nuclear medicine examinations.
The Department is equipped with a classical (2-headed) gamma camera and a latest generation hybrid SPECT-CT camera. The latter combines a gamma ray detector (2 heads) with a helicoidal CT scanner. This technology makes it possible to obtain a complete evaluation of the functional and anatomical/morphological characteristics of the disease.
2) The PET-CT unit
Since June 2001, the Institut Jules Bordet has had a positron emission tomography (PET) centre. This centre was opened as part of a collaboration with other public hospitals in Brussels, within the IRIS hospital network. It is one of the 20 PET centres recognised by royal decree in Belgium. In 2016, this unit carried out 6000 PET-CT scans using different types of tracer.
3) Molecular radiotherapy
The Institut Jules Bordet is a reference centre for treatments with radionuclides, the treatment of thyroid cancer historically being performed with iodine-131 and with MIBG for neuroblastomas. More recently, the Institut Jules Bordet has been a pioneer in Belgium in the development of the radioembolisation of hepatic tumours with microspheres labelled with Yttrium-90, injected selectively into the hepatic artery and in Protein Receptor RadioTherapy (PRRT) with Lutetium-177 octreotate for the treatment of neuroendocrine tumours.
The treatments available at the Institut Jules Bordet:
- Lu177-octreotate (neuroendocrine tumours)
- Y90-microspheres (radioembolisation of hepatic tumours and metastases)
- iodine-131 (thyroid cancer)
- IMIBG (neuroblastoma)
- Y90-rituximab (CD20-positive lymphoma)
- Radium-223 (bone pain and/or metastases)
- Samarium-153 (bone pain and/or metastases)
The Department of Nuclear Medicine is the national reference unit where “Lymphology” is concerned. Indeed the nuclear medicine techniques make it easy to carry out a functional study of various pathologies of the lymphatic system. These techniques prove to be particularly useful in targeting certain oedemas (post-therapeutic “large arm” or “large leg” syndrome or primary or secondary lymphoedemas) and help in choosing the best treatment.
The Department of Nuclear Medicine is a training unit recognised for the training of doctors specialising in nuclear medicine (complete training programme).
Each year, it welcomes 1 or 2 young doctors training in nuclear medicine, as well as students on a masters in medicine course (1 or 2 per month). It organises regular seminars recognised to be part of in-service training of specialist doctors.
The Department also welcomes trainees training to be medical technologists.
The Department of Nuclear Medicine of the Institut Jules Bordet is the only service of the ULB network which provides systemic radionuclide cancer treatments (thyroid and neuroendocrine cancers). It has therefore become a national and international reference centre for specific training in “theranostics” and molecular radiotherapy.
ETUDE DE LA TOLERABILITÉ ET DE L’EFFICACITÉ DU 177LU-DOTATATE (PRRT) CHEZ LES PATIENTS ATTEINTS DE MYÉLOME MULTIPLE EN RECHUTE ET EXPRIMANT LES RÉCEPTEURS DE SOMATOSTATINE
Phase II prospective, multicentre study evaluating the utility of a an HER2-PET/CT combined with an FDG-PET/CT in identifying HER2 negative lesions that will not benefit from a new targeted treatment against HER2 : T-DM1 (ZEPHIR)
Étude de phase III, multicentrique, internationale, prospective, en ouvert, randomisée évaluant le 177Lu- PSMA-617 dans le traitement de patients atteints d’un cancer de la prostate résistant à la castration métastatique (CPRCm), positif au PSMA et évolutif
- Project leader : Carlos Artigas
- Financing/Support : Endocyte
Head of Department
Prof Patrick Flamen
Dr Carlos Artigas, Assistant Head of Clinic
Dr Géraldine Gebhart, Assistant Head of Clinic
Dr Ioannis Karfis, Assistant Head of Clinic
Dr Elçin Özalp, Assistant Head of Clinic
Dr Erwin Woff, Assistant Head of Clinic
Dr Ivan Duran Derijckere, Resident
Radiophysicists (Department of Radiophysics
Clémentine Marin, Radiophysicist
Gwennaëlle Marin, Radiophysicist / PhD Student in Medical Physics
Marie Christiane Yimo-Wadje (Physics control)
Coordination of radionuclide treatments and thyroid checkups
Pauwel Thijs (thyroid cancer)
CoreLab molecular imaging (ORILAB)
Thomas Guiot, Ing
Zéna Wimana, Radiopharmacy/pre-clinical imaging
Wendy Delbart, PhD Student/Research Assistant
Loubna Taraji Schiltz, Clinical Study Coordinator
Romain Barbieux, Assistant Clinical Research, Lymphology
Hugo Levillain, PhD Student in Medical Physics
Alyssa Hammouda (PET-Scan)
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Authors : Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
Year : 2019
Journal : Clin Pharmacol Ther
Volume : 106
Pages : 148-163
Unilateral Adrenalectomy Could Be a Valid Option for Primary Nodular Adrenal Disease: Evidence From Twins.
Authors : Kyrilli A, Lytrivi M, Bouquegneau MS, Demetter P, Lucidi V, Garcia C, Moreno-Reyes R, Tabarin A, Corvilain B, Driessens N
Year : 2019
Journal : J Endocr Soc
Volume : 3
Pages : 129-134
Radioembolization with <sup>90</sup>Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity.
Authors : Braat AJAT, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH
Year : 2019
Journal : Cardiovasc Intervent Radiol
Volume : 42
Pages : 413-425
3D Monte Carlo dosimetry of intraoperative electron radiation therapy (IOERT).
Authors : Alhamada H, Simon S, Philippson C, Vandekerkhove C, Jourani Y, Pauly N, VanGestel D, Reynaert N
Year : 2019
Journal : Phys Med
Volume : 57
Pages : 207-214
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
Authors : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134